

Update from the NCI Deputy Director

*Douglas R. Lowy
Deputy Director, National Cancer Institute
National Institutes of Health*

FNLACI Meeting
October 30, 2017



NATIONAL CANCER INSTITUTE


Dr. Sharpless: On board!

Dave Heimbrook

Thank you!



NCI APPROPRIATIONS 2013-2017 (in billions)



Continuing Resolution for Start of FY 2018

- Funding: October 1 - December 8
- Includes funding for Cancer Moonshot

NCI/NIH BUDGET PROCESS FOR REGULAR APPROPRIATION

STEP 1



White House OMB coordinates with federal agencies to formulate the President's budget proposal

STEP 2



Congressional appropriations committees consider President's proposal & prepare legislation

STEP 3



Congress reconciles & finalizes appropriations legislation & sends to the President

STEP 4



President signs the appropriations bill into law making funds available for NIH & NCI

FY 2018

FY 2017

Appropriations Committee Activities – FY18


House bill – July 2017

- NIH = + \$1.1 billion over FY17 enacted level
- NCI = + \$82 million over FY17 enacted level
- Additional \$300 million - 21st Century Cures Cancer Moonshot Funding

Senate bill – September 2017

- NIH = + \$2.0 billion over FY17 enacted level
- NCI = + \$169 million over FY17 enacted level
- Additional \$300 million - 21st Century Cures Cancer Moonshot Funding

National Cancer Institute Appropriations History (Dollars in Millions)



*Percent changes do not include 21st Century Cures funding

Importance of Research Supported by NCI's Regular Appropriation (1)

- Largely non-overlapping with Cancer Moonshot research activities
- A few ongoing examples:
 - Training the next generation of investigators
 - Investigator-initiated research
 - Most clinical trials and cancer cohorts
 - PMI Oncology
 - RAS initiative

Importance of Research Supported by NCI's Regular Appropriation (2)

- Some new initiatives:
 - National Cryo-Electron Microscopy Facility, FNLCR
 - FNLCR = Frederick National Laboratory for Cancer Research
 - <https://www.cancer.gov/research/resources/cryoem>
 - TMIST breast cancer screening trial
 - TMIST = Tomosynthesis Mammographic Imaging Screening Trial

TMIST Breast Cancer Screening Trial

- Collaboration with ECOG-ACRIN
- Primary goal: Determine if ***cumulative rate of advanced breast cancer*** in women undergoing screening with ***tomosynthesis plus digital mammography*** is reduced compared to ***digital mammography alone***
- RCT, 165,000 women 45-74
- Menopausal normal risk: biennial screens: 0, 24, 48 months
- Menopausal increased risk: annual screens: 0, 12, 24, 36, 48 months
- Biorepository

Blue Ribbon Panel Recommendations



The graphic features a dark blue header with the text "BLUE RIBBON PANEL 2016" in white and teal. Below this is the "CANCER MOONSHOT" logo, which consists of the words "CANCER MOONSHOT" in white with a white play button icon below it. A paragraph of text follows, stating: "The Blue Ribbon Panel presented its report to the National Cancer Advisory Board on September 7, 2016. NCI then transmitted the final revised version to the Vice President on October 17, 2016. The final report describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years." At the bottom, there are two hexagonal icons: one with a PDF icon and the text "Download the Complete Report", and another with a book and glasses icon and the text "Download an At-a-Glance". The background of the lower half is a light green grid of hexagons, some containing small images related to cancer research and patient care.

BLUE RIBBON PANEL 2016

CANCER MOONSHOT

The Blue Ribbon Panel presented its report to the National Cancer Advisory Board on September 7, 2016. NCI then transmitted the final revised version to the Vice President on October 17, 2016. The final report describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.

Download the Complete Report

Download an At-a-Glance

available at:
cancer.gov/brp

- A. Network for direct patient engagement
- B. Cancer immunotherapy translational science network
- C. Therapeutic target identification to overcome drug resistance
- D. Creation of a national cancer data ecosystem
- E. Fusion oncoproteins in pediatric cancer
- F. Symptom management research
- G. Precision prevention and early detection
- H. Retrospective analysis of biospecimens from patients treated with standard of care
- I. Creation of human tumor atlas
- J. Development of new enabling technologies

FY17 Cancer Moonshot funding: Initial Implementation of Blue Ribbon Panel Recommendations

- Pediatric Fusion Proteins
 - APCR supplement program
 - core resources
- Technology
 - APCR supplement program
 - IMAT RFA
 - PDX development centers
- Immunotherapy
 - biomarker development labs RFA for adult and pediatric; PACT
 - canine immunotherapy
 - expand CITN to include pediatrics
 - Clinical center lab
 - Autoimmune sequelae – collaboration with NIAID
- Therapeutic resistance RFA
- Retrospective risk stratification – resource development
- Human tumor atlas
 - Pilot projects
- Prevention and Early Detection
 - HPV vaccine trial
- Implementation Science
 - Symptom management (oral cancer agents)
 - Reduce over-screening
 - Tobacco control supplements

For new awards in FY18 – FY23: Cancer Moonshot Implementation Teams

- Implementation Teams aligned with BRP recommendations
- Composition: Staff from NCI & other Institutes
- Charge to each Implementation Team:
 - Develops and proposes initiatives for FY18 and beyond to help achieve a specific BRP Recommendation
 - Seeks input from cancer research community, including organizing workshops, etc.
 - Provides oversight and coordination of funded initiatives, including organizing meetings, providing supplements, etc.

Status of FY18 Moonshot RFAs

Moonshot Implementation Team	RFA	RFA Published
Network for Patient Engagement		
Pediatric Immunotherapy Network	1) Pediatric Immunotherapy Discovery and Development Network (PI-DDN): Specialized Centers (U54) 2) Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01)	
Adult Immunotherapy Network	1) Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01) 2) Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01) 3) Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24) 4) Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)	
Target ID to Overcome Drug Resistance	1) Mechanisms of Cancer Drug Resistance and Sensitivity Coordinating Center (U24)	
National Cancer Data Ecosystem		
Fusion Oncoproteins	1) Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54)	RFA-CA-17-049

Status of FY18 Moonshot RFAs (Cont.)

Moonshot Implementation Team	RFA	RFA Published
Symptom Management	1) Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)	
High Risk Cancers	1) Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)	RFA-CA-17-041
Prevention and Screening	1) Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3) 2) Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS) (U24)	
Retrospective Analysis of Biospecimens		
Generation of Human Tumor Atlases	1) Human Tumor Atlas Research Centers (U2C) 2) Pre-Cancer Atlas (PCA) Research Centers (U2C) 3) Human Tumor Atlas Network Data Coordinating Center (U24)	
Development of New Technologies	1) Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33)	RFA-CA-17-023



NATIONAL CANCER INSTITUTE